Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 6/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610267 | 0.84 | CDC7 (0.41) | CDC7CDK2TTBK1MAP3K14RPS6KA5 | |
| SCHEMBL16610255 | 0.84 | CDC7 (0.47) | CDC7CDK2TTBK1MAP3K14RPS6KA5 | |
| SCHEMBL18585632 | 0.77 | CDC7 (0.54) | CDC7CDK2RPS6KA5ROCK1LCK | |
| SCHEMBL16610272 | 0.75 | CDC7 (0.71) | CDC7CDK2TTBK1MAP3K14ROCK1 | |
| SCHEMBL20476705 | 0.68 | PIK3CB (0.49) | — | |
| SCHEMBL30219552 | 0.65 | MAPKAPK2 (0.56) | MAP3K14LCKKITSRC | |
| SCHEMBL28986302 | 0.65 | MAP3K14 (0.49) | CDC7CDK2MAP3K14ROCK1FGFR1 | |
| SCHEMBL28986271 | 0.65 | MAP3K14 (0.50) | CDC7CDK2MAP3K14ROCK1FGFR1 | |
| SCHEMBL30219561 | 0.65 | MAP3K14 (0.50) | CDC7CDK2MAP3K14ROCK1FGFR1 | |
| SCHEMBL28986278 | 0.65 | MAPKAPK2 (0.56) | MAP3K14LCKKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071566-B1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-15 | — | — | EP | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| WO-2015044267-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CDC7 620/4885CDK2 784/4885TTBK1 578/4885 |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K12 | CDC7 548/4885CDK2 673/4885TTBK1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.